Cargando…

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia

Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different categories of drugs for concomitant disorders. Demented patients may take >6–10 drugs/day with the consequent ri...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cacabelos, Ramon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246738/ https://www.ncbi.nlm.nih.gov/pubmed/32357528 http://dx.doi.org/10.3390/ijms21093059

Ejemplares similares

Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
por: Vuic, Barbara, et al.
Publicado: (2023)

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
por: Cacabelos, Ramón
Publicado: (2017)

Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders
por: Cacabelos, Ramón
Publicado: (2009)

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
por: Cacabelos, Ramón, et al.
Publicado: (2015)

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
por: Cacabelos, Ramón, et al.
Publicado: (2010)

Precision Medicine & Pharmacogenomics: Personalized Medication in Neuropsychiatric Disorders using AI and telepsychiatry
por: Gkouvas, N.
Publicado: (2022)

Terra incognita—cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia
por: Tan, Rachel H., et al.
Publicado: (2015)

Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
por: Teijido, Óscar, et al.
Publicado: (2017)

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
por: Ng, Kok Pin, et al.
Publicado: (2019)

mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders
por: Ryskalin, Larisa, et al.
Publicado: (2018)

Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
por: Carril, Juan C., et al.
Publicado: (2017)

Cognitive dysfunction and dementia in movement disorders
por: Barbosa, Egberto Reis, et al.
Publicado: (2016)

New Strategies for the Treatment of Neuropsychiatric Disorders Based on Reelin Dysfunction
por: Tsuneura, Yumi, et al.
Publicado: (2022)

Neuropsychiatric symptoms in Brazilians with mild cognitive impairment and dementia
por: Wilson, Robert S., et al.
Publicado: (2021)

Dementia model mice exhibited improvements of neuropsychiatric symptoms as well as cognitive dysfunction with neural cell transplantation
por: Murayama, Masanori A., et al.
Publicado: (2021)

Bipolar Disorder: Clinical Perspectives and Implications with Cognitive Dysfunction and Dementia
por: Lopes, R., et al.
Publicado: (2012)

Neuropsychiatric Symptoms in Parkinson's Disease with Mild Cognitive Impairment and Dementia
por: Leroi, Iracema, et al.
Publicado: (2012)

Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia
por: Solvang, Stein-Erik Hafstad, et al.
Publicado: (2019)

Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia
por: Lee, Philip E, et al.
Publicado: (2006)

Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
por: Nowrangi, Milap A, et al.
Publicado: (2015)

Editorial: Temporal lobe dysfunction in neuropsychiatric disorder
por: Gao, Yujun, et al.
Publicado: (2022)

The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders
por: Lai, Claudia KY
Publicado: (2014)

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
por: Schwartz, Avery, et al.
Publicado: (2009)

Pharmacogenomic Characterization in Bipolar Spectrum Disorders
por: Fortinguerra, Stefano, et al.
Publicado: (2019)

Pharmacogenomics of Lithium Response in Bipolar Disorder
por: Vecera, Courtney M., et al.
Publicado: (2021)

Mitochondria under the spotlight: On the implications of mitochondrial dysfunction and its connectivity to neuropsychiatric disorders
por: Zilocchi, Mara, et al.
Publicado: (2020)

Autoantibodies in Neuropsychiatric Disorders
por: Hoffmann, Carolin, et al.
Publicado: (2016)

Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA
por: Phan, Stephanie V., et al.
Publicado: (2019)

Nuclear organization and 3D chromatin architecture in cognition and neuropsychiatric disorders
por: Medrano-Fernández, Alejandro, et al.
Publicado: (2016)

Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia
por: Alonso-Lana, Silvia, et al.
Publicado: (2020)

Neuropsychiatric symptoms and severity of dementia
por: Caldas, Gustavo Henrique de Oliveira, et al.
Publicado: (2013)

Epigenetic RELN Dysfunction in Schizophrenia and Related Neuropsychiatric Disorders
por: Guidotti, Alessandro, et al.
Publicado: (2016)

The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
por: Morris, Gerwyn, et al.
Publicado: (2015)

The genetics of neuropsychiatric disorders
por: Bray, Nicholas J., et al.
Publicado: (2018)

Pharmacogenomics and the Management of Mood Disorders—A Review
por: Kleine Schaars, Kristian, et al.
Publicado: (2023)

Neuropsychiatric Symptoms of Dementia: Consent, Quality of Life, and Dignity
por: Passmore, Michael J.
Publicado: (2013)

Assessment of neuropsychiatric symptoms in dementia: toward improving accuracy
por: Stella, Florindo
Publicado: (2013)

The Histaminergic System in Neuropsychiatric Disorders
por: Cheng, Li, et al.
Publicado: (2021)

Gut Bacteria and Neuropsychiatric Disorders
por: Dicks, Leon M. T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_50u92oh9o2pueajkd9dadoqu5m